Penserra Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Penserra Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9	Closed	–	–	1112
2024 Q3	$0	Sell	9 -3	-25%	-$251	﹤0.01%	1120
2024 Q2	$1K	Sell	12 -3	-20%	-$250	﹤0.01%	1210
2024 Q1	$1K	Hold	15	–	–	﹤0.01%	1179
2023 Q4	$1K	Hold	15	–	–	﹤0.01%	1223
2023 Q3	$1K	Buy	15 +5	+50%	+$445	﹤0.01%	1212
2023 Q2	$0	Hold	10	–	–	﹤0.01%	1267
2023 Q1	$0	Hold	10	–	–	﹤0.01%	1125
2022 Q4	$1K	Buy	+10	New	+$939	﹤0.01%	1079
2020 Q2	–	Sell	-1,115	Closed	-$106K	–	812
2020 Q1	$106K	Buy	+1,115	New	+$96.1K	0.01%	553
2019 Q3	–	Sell	-1,596	Closed	-$136K	–	859
2019 Q2	$136K	Buy	+1,596	New	+$137K	0.01%	443
2017 Q1	–	Sell	-224	Closed	-$18K	–	588
2016 Q4	$18K	Buy	224 +39	+21%	+$3.35K	﹤0.01%	680
2016 Q3	$17K	Buy	185 +74	+67%	+$6.97K	﹤0.01%	602
2016 Q2	$9K	Buy	111 +41	+59%	+$3.49K	﹤0.01%	719
2016 Q1	$5	Buy	70 +2	+3%	+$163	﹤0.01%	828
2015 Q4	$7K	Buy	+68	New	+$7.1K	﹤0.01%	602

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Penserra Capital Management's BMRN Position: Q4 2024 in Review

Penserra Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 9 shares.

Penserra Capital Management first reported a position in BMRN in Q4 2015 and held it in 15 quarters. The position peaked at $136K in Q2 2019. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Penserra Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Penserra Capital Management sold 9 BioMarin Pharmaceuticals shares in Q4 2024.
Penserra Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 15 quarters.
Penserra Capital Management's BioMarin Pharmaceuticals position peaked at $136K in Q2 2019.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Penserra Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.